Radiosensitization with Hyperthermia and Chemotherapeutic Agents: Effects on Linear-Quadratic Parameters of Radiation Cell Survival Curves

Franken, Nicolaas A.P.; Hovingh, Suzanne E.; Oei, Arlene L.; Cobussen, Paul; Bergs, Judith; Bree, Chris van; Rodermond, Hans M.; Stalpers, Lukas J.A.; Kok, Petra; Barendsen, G.W.; Crezee, J.

doi:10.5772/34939

Cited by 5 publications

(7 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of tumors treated with extracranial SBRT are grouped in Fig. 4(a) for survival curves of squamous cell cancer (SCC) cell lines: 24‐hour delay and no delay plated SW1573 — a lung SCC, 25 DaFu — a head and neck SCC 26 and SKX — a base of tongue SCC 26 and in Fig. 4(b) for in‐vivo lung cancer lines other than SCC including HX147 — large‐cell carcinomas, HX149M — variant small cell carcinomas, HX144 ‐Adenocarcinomas, and HC12 — classical small cell lung cancer (SCLC) 27 .…”

Section: Resultsmentioning

confidence: 99%

“…UMA modeling of survival curves of tumors for SBRT: 4(a) human lung squamous cell cancer (SCC) — SW1573 cells with 24‐hour delay plates and immediate plates after irradiation redrawn data from Franken NAP et al 25 …”

Section: Resultsmentioning

confidence: 99%

“…4. UMA modeling of survival curves of tumors for SBRT: 4(a) human lung squamous cell cancer (SCC) -SW1573 cells with 24-hour delay plates and immediate plates after irradiation redrawn data from Franken NAP et al 25 . In vitro data of DaFu Cellsa H&N SCC and SKXa base of tongue SCC redrawn from Menegakis A et al 26 .…”

Section: B α α/β and Edq2 Determined With The Uma Modelmentioning

confidence: 99%

See 2 more Smart Citations

A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)

Miyamoto

Wang

et al. 2021

Medical Physics

View full text Add to dashboard Cite

Application of linear-quadratic (LQ) model to large fractional dose treatments is inconsistent with observed cell survival curves having a straight portion at high doses. We have proposed a unified multi-activation (UMA) model to fit cell survival curves over the entire dose range that allows us to calculate EQD2 for hypofractionated SBRT, SRT, SRS, and HDRB. Methods: A unified formula of cell survival S ¼ n= e D Do þ n À 1 using only the extrapolation number of n and the dose slope of D o was derived. Coefficient of determination, R 2 , relative residuals, r, and relative experimental errors, e, normalized to survival fraction at each dose point, were calculated to quantify the goodness in modeling of a survival curve. Analytical solutions for α and β, the coefficients respectively describe the linear and quadratic parts of the survival curve, as well as the α/β ratio for the LQ model and EQD2 at any fractional doses were derived for tumor cells undertaking any fractionated radiation therapy. Results: Our proposed model fits survival curves of in-vivo and in-vitro tumor cells with R 2 > 0.97 and r < e. The predicted α, β, and α/β ratio are significantly different from their values in the LQ model. Average EQD2 of 20-Gy SRS of glioblastomas and melanomas metastatic to the brain, 10-Gy × 5 SBRT of the lung cancer, and 7-Gy × 5 HDRB of endometrial and cervical carcinomas are 36.7 (24.3-48.5), 114.1 (86.6-173.1),, and 45.5 (35-52.6) Gy, different from the LQ model estimates of 50.0, 90.0, and 49.6 Gy, respectively. Conclusion: Our UMA model validated through many tumor cell lines can fit cell survival curves over the entire dose range within their experimental errors. The unified formula theoretically indicates a common mechanism of cell inactivation and can estimate EQD2 at all dose levels.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: B α α/β and Edq2 Determined With The Uma Modelmentioning

confidence: 99%

See 1 more Smart Citation

A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)

Miyamoto

Wang

et al. 2021

Medical Physics

View full text Add to dashboard Cite

show abstract

“…When activated by neutrons, the radioisotope 187 Wolfram (tungsten) is formed. These magnetic NPs are thus ideal candidates for advanced radiopharmaceutical applications [118], based on the well-known synergistic interaction between hyperthermia and radiotherapy [119][120][121].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

The role of recent nanotechnology in enhancing the efficacy of radiation therapy

Bergs

Wacker

Hehlgans

et al. 2015

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

“…The effect of fractionated radiation dosing on GBM is studied using the linearquadratic (L-Q) model. 14–17 Powathil and colleagues 18 consider a spatiotemporal brain tumor model that includes effects from both radiotherapy and chemotherapy. Patient-specific models of glioblastoma are developed in Rockne et al 19 and Esteller et al 20 to predict patient response to radiotherapy and to determine optimal dosing strategies.…”

Section: Introductionmentioning

confidence: 99%

Glioblastoma Recurrence and the Role of O⁶-Methylguanine–DNA Methyltransferase Promoter Methylation

Storey

Leder

Hawkins-Daarud

et al. 2019

JCO Clinical Cancer Informatics

View full text Add to dashboard Cite

Tumor recurrence in glioblastoma multiforme (GBM) is often attributed to acquired resistance to the standard chemotherapeutic agent, temozolomide (TMZ). Promoter methylation of the DNA repair gene MGMT (06-methylguanine–DNA methyltransferase) has been associated with sensitivity to TMZ, whereas increased expression of MGMT has been associated with TMZ resistance. Clinical studies have observed a downward shift in MGMT methylation percentage from primary to recurrent stage tumors; however, the evolutionary processes that drive this shift and more generally the emergence and growth of TMZ-resistant tumor sub-populations are still poorly understood. Here, we develop a mathematical model, parameterized using clinical and experimental data, to investigate the role of MGMT methylation in TMZ resistance during the standard treatment regimen for GBM—surgery, chemotherapy, and radiation. We first found that the observed downward shift in MGMT promoter methylation status between detection and recurrence cannot be explained solely by evolutionary selection. Next, our model suggests that TMZ has an inhibitory effect on maintenance methylation of MGMT after cell division. Finally, incorporating this inhibitory effect, we study the optimal number of TMZ doses per adjuvant cycle for patients with GBM with high and low levels of MGMT methylation at diagnosis.

show abstract

Radiosensitization with Hyperthermia and Chemotherapeutic Agents: Effects on Linear-Quadratic Parameters of Radiation Cell Survival Curves

Cited by 5 publications

References 103 publications

A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)

A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)

The role of recent nanotechnology in enhancing the efficacy of radiation therapy

Glioblastoma Recurrence and the Role of O⁶-Methylguanine–DNA Methyltransferase Promoter Methylation

Contact Info

Product

Resources

About

Radiosensitization with Hyperthermia and Chemotherapeutic Agents: Effects on Linear-Quadratic Parameters of Radiation Cell Survival Curves

Cited by 5 publications

References 103 publications

A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)

A unified multi‐activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)

The role of recent nanotechnology in enhancing the efficacy of radiation therapy

Glioblastoma Recurrence and the Role of O6-Methylguanine–DNA Methyltransferase Promoter Methylation

Contact Info

Product

Resources

About

Glioblastoma Recurrence and the Role of O⁶-Methylguanine–DNA Methyltransferase Promoter Methylation